BIIB vs GILD
BIIB and GILD side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BIIBBIOGEN INC. | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Market cap | $37.18B | $211.28B |
| P/E (TTM) | 108.9 | 25.1 |
| P/B | 2.51 | 16.20 |
| P/S | 3.7x | 7.2x |
| Dividend yield | — | 1.89% |
| Revenue | $10.30B(TTM) | $30.99B(TTM) |
| Revenue growth (YoY) | 2.2% | 2.4% |
| Net income | $347.60M(TTM) | -$3.86B(TTM) |
| Earnings growth (YoY) | -20.8% | 1672.9% |
| EPS, diluted | $2.31(TTM) | $-3.13(TTM) |
| EBIT margin | 28.7% | 34.0% |
| ROE | 8.7% | 65.3% |
| ROIC | 12.3% | 25.7% |
| Piotroski F | 3/9 | — |
| 1y total return | +64.8% | +42.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BIIB vs GILD
| Metric | BIIB | GILD |
|---|---|---|
| End value | $10.2K | $28.8K |
| Total return | +2.5% | +187.6% |
| CAGR | +0.2% | +10.8% |
| Volatility | 41.1% | 25.6% |
| Sharpe | 0.10 | 0.36 |
| Sortino | 0.16 | 0.54 |
| Max drawdown | -72.7% | -30.5% |
Based on 2600 common trading days, 2016-07-01 → 2026-11-03 · risk-free 4.21% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)